Trials / Completed
CompletedNCT03359876
Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction
Evaluation of Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction Treated With Warfarin or Reduced Dose Rivaroxaban
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 16,000 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to evaluate the effectiveness and safety of the reduced dose rivaroxaban (15 mg once daily) as compared to warfarin in non-valvular atrial fibrillation (NVAF) patients with renal dysfunction in routine clinical practice. The study has a retrospective design, and will be conducted in the US Truven Health MarketScan Commercial Claims and Medicare Supplemental Databases
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivaroxaban (Xarelto, BAY59-7939) | 15 mg, once daily |
| DRUG | Warfarin sodium | Individually adjusted dose |
Timeline
- Start date
- 2017-12-01
- Primary completion
- 2019-03-29
- Completion
- 2019-03-29
- First posted
- 2017-12-02
- Last updated
- 2019-12-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03359876. Inclusion in this directory is not an endorsement.